136295-80-2

Usage

Uses

Used in Organic Synthesis:
3,5-DIMETHYL-4-(TRIBUTYLSTANNYL)ISOXAZOLE is used as a reagent for facilitating various organic reactions, such as cross-coupling reactions, due to its unique reactivity and the presence of the tributylstannyl group.
Used in Pharmaceutical Development:
In the Pharmaceutical Industry, 3,5-DIMETHYL-4-(TRIBUTYLSTANNYL)ISOXAZOLE is used as a building block for the synthesis of complex organic molecules, contributing to the development of new pharmaceuticals.
Used in Agrochemical Development:
Similarly, in the Agrochemical Industry, 3,5-DIMETHYL-4-(TRIBUTYLSTANNYL)ISOXAZOLE serves as a key component in the synthesis of novel compounds for agricultural applications, potentially leading to the creation of new agrochemicals.

InChI:InChI=1/C5H6NO.3C4H9.Sn/c1-4-3-5(2)7-6-4;3*1-3-4-2;/h1-2H3;3*1,3-4H2,2H3;/rC17H33NOSn/c1-6-9-12-20(13-10-7-2,14-11-8-3)17-15(4)18-19-16(17)5/h6-14H2,1-5H3

Upstream product

• 10557-85-4 4-iodo-3,5-dimethylisoxazole 
• 1461-22-9 tributyltin chloride 
• 300-87-8 3,5-dimethyl-1,2-oxazole 

Downstream Products

• 136295-82-4 3,5-dimethyl-4-(2-nitro-phenyl)-isoxazole 
• 1360605-04-4 5-chloro-4-(3-chloro-4-hydroxyphenyl)-3-(3,5-dimethylisoxazol-4-yl)-N'-hydroxythiophene-2-carboximidamide 
• 1360605-03-3 4-(3-chloro-4-hydroxyphenyl)-3-(3,5-dimethylisoxazol-4-yl)-N'-hydroxythiophene-2-carboximidamide 
• 1360605-28-2 5-chloro-4-(3-chloro-4-methoxyphenyl)-3-(3,5-dimethylisoxazol-4-yl)thiophene-2-carbonitrile 
• 1360605-27-1 4-(3-chloro-4-methoxyphenyl)-3-(3,5-dimethylisoxazol-4-yl)thiophene-2-carbonitrile 
• 1360605-26-0 3-(3,5-dimethylisoxazol-4-yl)-4-(4-methoxyphenyl)thiophene-2-carbonitrile 
• 1290138-30-5 5-(3,5-dimethylisoxazol-4-yl)-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole-4-carbonitrile 
• 1290137-76-6 5-(3,5-dimethylisoxazol-4-yl)-1-(4-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carbaldehyde oxime 
• 1290138-31-6 5-(3,5-dimethylisoxazol-4-yl)-1-(4-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carbaldehyde 
• 1290137-71-1 5-(3,5-dimethylisoxazol-4-yl)-1-(4-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carboxamide 
• 1290137-74-4 5-(3,5-dimethylisoxazol-4-yl)-N'-hydroxy-1-(4-hydroxyphenyl)-3-methyl-4H-pyrazole-4-carboximidamide 
• 1290137-97-1 5-(3,5-dimethylisoxazol-4-yl)-1-(4-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carbonitrile 

Relevant academic research and scientific papers

A New Binucleating Ligand Based on Anthracene and Its Cofacial Dirhodium(I) and Diiridium(I) Complexes

A new bis(β-keto enamine) ligand (2a, ABIH2) containing a 1,8-anthracenediyl bridging group has been synthesized by a four-step procedure that relies on the Pd-catalyzed cross-coupling between (3,5-dimethylisoxazol-4-yl)-trialkyltin and 1,8-dibromoanthraquinone or -anthracene. The molecular structures of the 1,8-bis(3,5-dimethylisoxazol-4-yl)anthraquinone (8) and -anthracene (10) intermediates were determined by X-ray analysis. Crystal data for 8: orthorhombic, space group Pbca; a = 14.351 (2), b = 11.932 (1), c = 23.278 (2) A?; V = 3986 (1) A?3; Z = 8; R = 0.057 for 2615 reflections. Crystal data for 10: orthorhombic, space group P212121; a = 7.104 (1), b = 12.805 (1), c = 22.280 (2) A?; V = 2026.7 (6) A?3; Z = 4; R = 0.066 for 3423 reflections. The rigid ABIH2 ligand, whose chelating moieties are constrained to be cofacial, allows the preparation of a new family of cofacial bimetallic complexes (ABI)[ML2]2 with controllable environments around the metal centers. Two novel cofacial binuclear complexes 4 and 5, with ML2 = dicarbonylrhodium(I) and (η4-1,5-cyclooctadiene)iridium(I), have been synthesized by reaction of ABIH2 with [(μ-Cl)Rh(CO)2]2 and [(μ-Cl)Ir(COD)]2, respectively. NMR data indicate the formation of meso and racemic atropisomers for 2a, 4, and 5.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

SUBSTITUTED PYRAZOLES AS ESTROGEN RECEPTOR LIGANDS

The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.